Literature DB >> 23659393

Can the presence of significant coagulopathy be useful to exclude symptomatic acute pulmonary embolism?

K M Ho1, J A Tan.   

Abstract

Thrombocytopenia or an abnormal coagulation profile is not rare in hospitalised patients who have symptoms consistent with acute pulmonary embolism (PE). Theoretically, coagulopathy is more likely to occur in patients with pneumonia than acute PE. This study aimed to assess whether the presence of coagulopathy could be used to exclude acute PE in patients with symptoms and signs consistent with acute PE. In this study, a significant coagulopathy was defined as a platelet count <100×10(9)/l, an international normalised ratio >1.5, or activated partial thromboplastin time >50 seconds. Patients treated with systemic anticoagulants prior to computed tomography pulmonary angiography were excluded. Of the 986 consecutive patients who required computed tomography pulmonary angiography to exclude acute PE over a four-month period in five hospitals in Western Australia, acute PE was confirmed in 149 patients (15.1%). The incidence of coagulopathy was not significantly different between those with and without acute PE (4 vs 7%, respectively; P=0.161) and between those with and without pneumonia (8 vs 7%, respectively; P=0.505). Positive and negative likelihood ratios of coagulopathy in differentiating acute PE or pneumonia were both unsatisfactory. As a continuous predictor, platelet counts, international normalised ratio, activated partial thromboplastin time and plasma fibrinogen concentrations were also not useful in differentiating between acute PE and other pulmonary pathologies (areas under the receiver operating characteristic curve were all close to 0.5). In conclusion, the presence of significant acquired coagulopathy cannot be used to suggest pneumonia or exclude symptomatic acute PE when the prevalence or pre-test probability of acute PE is not low.

Entities:  

Keywords:  coagulation; diagnosis; pneumonia; sensitivity and specificity; venous thromboembolism

Mesh:

Substances:

Year:  2013        PMID: 23659393     DOI: 10.1177/0310057X1304100308

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  3 in total

1.  Thrombolysis during extended cardiopulmonary resuscitation for autoimmune-related pulmonary embolism.

Authors:  Jian-Ping Gao; Ke-Jing Ying
Journal:  World J Emerg Med       Date:  2015

2.  Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol.

Authors:  Kwok M Ho; Sudhakar Rao; Stephen Honeybul; Rene Zellweger; Bradley Wibrow; Jeffrey Lipman; Anthony Holley; Alan Kop; Elizabeth Geelhoed; Tomas Corcoran
Journal:  BMJ Open       Date:  2017-07-12       Impact factor: 2.692

3.  Value of D-dimer in predicting various clinical outcomes following community-acquired pneumonia: A network meta-analysis.

Authors:  Jiawen Li; Kaiyu Zhou; Hongyu Duan; Peng Yue; Xiaolan Zheng; Lei Liu; Hongyu Liao; Jinlin Wu; Jinhui Li; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.